* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Thursday, October 23, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Reba McEntire Details Personal Relationship With Late Stepson Brandon Blackstock – KNDU

    Reba McEntire Shares Emotional Tribute to Her Late Stepson Brandon Blackstock

    Sacramento city leaders approve adding 2 entertainment zones in midtown – CBS News

    Sacramento City Leaders Approve Two Thrilling New Entertainment Zones in Midtown

    AMC brings first new Dolby Experience to Gwinnett since 2017 – Wyoming News Now

    AMC Launches First New Dolby Experience in Gwinnett Since 2017

    Hetzel Design: blending architecture and entertainment – Blooloop

    Hetzel Design: Where Architecture and Entertainment Unite in Perfect Harmony

    Country music legend rushed to hospital year after heart surgery. Here’s what we know – PennLive.com

    Country Music Legend Rushed to Hospital One Year After Heart Surgery – What’s Happening Now?

    Strictly Come Dancing results: Chris Robshaw is eliminated while drag queen La Voix escapes dance-off – Yahoo

    Strictly Come Dancing results: Chris Robshaw is eliminated while drag queen La Voix escapes dance-off – Yahoo

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Next steps: Technology opens new options for greater mobility – Missouri Independent

    Next Steps: How Technology is Opening Exciting New Doors to Greater Mobility

    Rydberg Technologies Inc. Announces Launch of Rydberg Photonics in Berlin – The Quantum Insider

    Rydberg Technologies Launches Exciting New Photonics Division in Berlin

    A look into new technology at Columbia University that could help prevent a dangerous pregnancy complication – ABC7 New York

    A look into new technology at Columbia University that could help prevent a dangerous pregnancy complication – ABC7 New York

    Office Technology: Dealers’ Managed IT Revenue up Nearly 30% – The Cannata Report –

    Office Technology: Dealers’ Managed IT Revenue up Nearly 30% – The Cannata Report –

    3 E Network Technology Group Limited Closes $1.5 Million Convertible Promissory Note Offering – Quiver Quantitative

    3 E Network Technology Group Limited Closes $1.5 Million Convertible Promissory Note Offering – Quiver Quantitative

    3 Technology Stocks to Buy Now – Yahoo Finance

    3 Must-Buy Tech Stocks You Can’t Afford to Miss Right Now

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Reba McEntire Details Personal Relationship With Late Stepson Brandon Blackstock – KNDU

    Reba McEntire Shares Emotional Tribute to Her Late Stepson Brandon Blackstock

    Sacramento city leaders approve adding 2 entertainment zones in midtown – CBS News

    Sacramento City Leaders Approve Two Thrilling New Entertainment Zones in Midtown

    AMC brings first new Dolby Experience to Gwinnett since 2017 – Wyoming News Now

    AMC Launches First New Dolby Experience in Gwinnett Since 2017

    Hetzel Design: blending architecture and entertainment – Blooloop

    Hetzel Design: Where Architecture and Entertainment Unite in Perfect Harmony

    Country music legend rushed to hospital year after heart surgery. Here’s what we know – PennLive.com

    Country Music Legend Rushed to Hospital One Year After Heart Surgery – What’s Happening Now?

    Strictly Come Dancing results: Chris Robshaw is eliminated while drag queen La Voix escapes dance-off – Yahoo

    Strictly Come Dancing results: Chris Robshaw is eliminated while drag queen La Voix escapes dance-off – Yahoo

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Next steps: Technology opens new options for greater mobility – Missouri Independent

    Next Steps: How Technology is Opening Exciting New Doors to Greater Mobility

    Rydberg Technologies Inc. Announces Launch of Rydberg Photonics in Berlin – The Quantum Insider

    Rydberg Technologies Launches Exciting New Photonics Division in Berlin

    A look into new technology at Columbia University that could help prevent a dangerous pregnancy complication – ABC7 New York

    A look into new technology at Columbia University that could help prevent a dangerous pregnancy complication – ABC7 New York

    Office Technology: Dealers’ Managed IT Revenue up Nearly 30% – The Cannata Report –

    Office Technology: Dealers’ Managed IT Revenue up Nearly 30% – The Cannata Report –

    3 E Network Technology Group Limited Closes $1.5 Million Convertible Promissory Note Offering – Quiver Quantitative

    3 E Network Technology Group Limited Closes $1.5 Million Convertible Promissory Note Offering – Quiver Quantitative

    3 Technology Stocks to Buy Now – Yahoo Finance

    3 Must-Buy Tech Stocks You Can’t Afford to Miss Right Now

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

Combination Shows Promise in Metastatic ESR1-Mutant Breast Cancer

January 4, 2024
in Health
Combination Shows Promise in Metastatic ESR1-Mutant Breast Cancer
Share on FacebookShare on Twitter

A novel drug combination led to clinically meaningful antitumor activity in metastatic ESR1-mutated, estrogen receptor-positive (ER+)/HER2-negative breast cancer that had progressed on CDK4/6 inhibition, a small prospective study showed.

Adding the selective estrogen receptor modulator (SERM) lasofoxifene to abemaciclib (Verzenio) resulted in a median progression-free survival (PFS) of 56 weeks, and a 24-week clinical benefit rate (CBR) of 65.5%. The combination was well tolerated with no new or unexpected toxicities and low rates of grade ≥3 toxicity.

The findings supported the initiation of a phase III randomized trial of the combination, reported Senthil Damodaran, MD, PhD, of the University of Texas MD Anderson Cancer Center in Houston, and co-authors in Annals of Oncology.

“All patients in ELAINE 2 had baseline ESR1 mutations, which are associated with a less favorable prognosis,” the authors pointed out during their discussion of the results. “Two of the four patients who developed rapid disease progression after 3-4 months on prior abemaciclib-based treatment experienced durable clinical benefit with lasofoxifene plus abemaciclib in ELAINE 2, suggesting that lasofoxifene contributes substantially to PFS outcomes and may synergistically interact with abemaciclib in modulating ER- and CDK-signaling cross-talk.”

A second study reported in the same issue of the journal showed no statistically significant clinical benefits with lasofoxifene versus the selective estrogen receptor degrader (SERD) fulvestrant in metastatic ESR1-mutated, ER+/HER2- breast cancer, but all clinical endpoints favored lasofoxifene, reported Matthew Goetz, MD, of the Mayo Clinic in Rochester, Minnesota, and co-authors.

In both studies, investigators examined dynamic changes in ESR1 allelic fraction during lasofoxifene treatment, which revealed significant reductions in mutant allelic fraction for several variants, noted the author of an accompanying editorial.

“Lasofoxifene demonstrated impressive target engagement across a wide spectrum of ESR1 variants,” wrote Seth Wander, MD, Massachusetts General Hospital and Harvard Medical School in Boston. “Emerging evidence supports the unsurprising notion that different ESR1 mutations convey distinct impacts on disease progression and therapeutic resistance.”

Ongoing studies “will foster new opportunities and new questions,” Wander continued. “Will there be a role for these agents as monotherapy, or will we continue to rely on combinations with other targeted agents? And which partner will provoke optimal benefit with these novel antiestrogens … As we develop these therapeutic strategies, we must remain focused on expanding our understanding of the molecular pathways driving progression in each individual patient.”

The open-label, multicenter, phase II ELAINE 2 trial reflected the evolving understanding of ESR1 mutations’ effect on ER+ breast cancer, including endocrine resistance, metastasis, and poor outcomes, Damodaran and co-authors noted in their introduction. Current systemic options for ESR1-mutated, HR+/HER2- metastatic breast cancer post-CDK4/6 inhibition are limited, and no established standard has emerged.

Recent small studies have shown modest clinical benefit from combined treatment with a CDK4/6 inhibitor and a SERD for ESR1-mutated advanced HR+ breast cancer after progression on CDK4/6 inhibition, underscoring the need for new and novel approaches, the authors continued. Lasofoxifene reduced the incidence of invasive ER+ breast cancer in a randomized trial in osteoporosis. Additionally, lasofoxifene demonstrated superior antitumor activity versus fulvestrant in a preclinical model of ESR1-mutated metastatic breast cancer, either alone or in combination with palbociclib (Ibrance).

Following the “encouraging antitumor activity” of lasofoxifene in the ELAINE 1 trial reported by Goetz and colleagues, ELAINE 2 was initiated to evaluate lasofoxifene’s safety and efficacy in combination with abemaciclib in metastatic ER+/HER2- breast cancer associated with ESR1 mutations.

ELAINE 2 included 29 patients, all with metastatic HR+/HER2- breast cancer and acquired ESR1 mutations. All the patients had disease that had progressed on prior systemic therapy, including CDK4/6 inhibition in 28 of 29 cases. Treatment consisted of lasofoxifene plus abemaciclib (regardless of the prior CDK4/6 inhibitor, which included abemaciclib in four cases).

Treatment continued until disease progression or development of unacceptable toxicity. The primary endpoint was safety/tolerability of the combination, and PFS was a secondary endpoint. The most common all-grade treatment emergent adverse events (TEAEs) included diarrhea (82.8%), nausea (51.7%), fatigue (37.9%), vomiting (31.0%), anemia (27.6%), dyspnea (27.6%), decreased white blood cell count (27.6%), and increased blood creatinine (24.1%).

Two patients developed grade 4 neutropenia. The most common grade 3 TEAEs were anemia (10.3%), hypokalemia (10.3%), neutropenia (6.9%), and fall (6.9%). No patient died during the study. One patient discontinued because of grade 2 diarrhea.

In addition to the median PFS exceeding 1 year, 6-month PFS was 76.1%, 12-month PFS was 56.1%, and 18-month PFS was 38.8%. The objective response rate was 55.6% among 18 patients with measurable lesions. ESR1-mutant circulating tumor DNA allele fraction decreased in 21 of 26 evaluable patients from baseline to week 4.

The ELAINE 1 trial included 103 patients with metastatic ESR1-mutated metastatic HR+/HER2- breast cancer. The patients were randomized to lasofoxifene or fulvestrant, and the primary endpoint was PFS.

Patients assigned to lasofoxifene had a median PFS of 24.2 weeks versus 16.2 weeks for the fulvestrant arm (P=0.138). CBR (36.5% vs 21.6%), objective response (13.2% vs 2.9%), 6-month PFS (53.4% vs 37.9%), and 12-month PFS (30.7% vs 14.1%) all favored lasofoxifene, but none of the differences achieved statistical significance, Goetz and co-authors reported.

author['full_name']

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Disclosures

The ELAINE trials were supported by Sermonix Pharmaceuticals.

Damodaran disclosed relationships with EMD Serono, Guardant Health, Taiho Pharmaceuticals, Novartis, and Sermonix Pharmaceuticals. Co-authors disclosed multiple relationships with industry.

Wander disclosed relationships with Foundation Medicine, Veracyte, Eli Lilly, Pfizer, Puma Biotechnology, Novartis, Biovica, AstraZeneca, 2ndMD, Genentech, Nuvation Bio, Regor Therapeutics, and Sermonix Pharmaceuticals.

Primary Source

Annals of Oncology

Source Reference: Damodaran S, et al “Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2” Ann Oncol 2023; DOI: 10.1016/j.annonc.2023.09.3104.

Secondary Source

Annals of Oncology

Source Reference: Goetz MP, et al “Lasofoxifene versus fulvestrant for ERD/HER2L metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial” Ann Oncol 2023; DOI: 10.1016/j.annonc.2023.09.3103.

Additional Source

Annals of Oncology

Source Reference: Wander SA “The ELAINE trials and the future of personalized therapy for hormone receptor-positive metastatic breast cancer” Ann Oncol 2023; DOI: 10.1016/j.annonc.2023.10.792.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/hematologyoncology/breastcancer/108115

Tags: Combinationhealthshows
Previous Post

Opening Blood-Brain Barrier to Deliver Alzheimer’s Drug Shows Promise

Next Post

Trial: Cleaner Cookstove Fuel Not Enough to Improve Infant Health

Vibrio pectenicida strain FHCF-3 is a causative agent of sea star wasting disease – Nature

Vibrio pectenicida strain FHCF-3 is a causative agent of sea star wasting disease – Nature

October 23, 2025
Condensation defying gravity – European Space Agency

Condensation defying gravity – European Space Agency

October 23, 2025
Guest educators bring fun environmental science to Kent middle school – MyEasternShoreMD

Guest Educators Ignite Passion for Environmental Science at Kent Middle School

October 23, 2025
Equity Lifestyle Properties, Inc. Profit Rises In Q3, Beats Estimates – Nasdaq

Equity Lifestyle Properties Delivers Impressive Q3 Profit, Exceeding All Expectations

October 23, 2025
Next steps: Technology opens new options for greater mobility – Missouri Independent

Next Steps: How Technology is Opening Exciting New Doors to Greater Mobility

October 23, 2025
American Football Betting Market Report 2025, with Profiles of ESPN, Caesers Entertainment, Entain, Fanatics Sports Betting, Betfred and Other Major and Innovative Companies – Yahoo Finance

American Football Betting Market Report 2025, with Profiles of ESPN, Caesers Entertainment, Entain, Fanatics Sports Betting, Betfred and Other Major and Innovative Companies – Yahoo Finance

October 23, 2025
UIPM 2025 Obstacle World Championships (OCR): All you need to know – Union Internationale de Pentathlon Moderne (UIPM)

Your Ultimate Guide to the 2025 Obstacle World Championships

October 23, 2025
PPPs in Bolivia: The future of our economy? – Dentons

Could PPPs Unlock Bolivia’s Path to Economic Prosperity?

October 23, 2025
Reba McEntire Details Personal Relationship With Late Stepson Brandon Blackstock – KNDU

Reba McEntire Shares Emotional Tribute to Her Late Stepson Brandon Blackstock

October 23, 2025
Mark Peterson receives inaugural APSA Career Achievement Award in Health Politics and Policy – UCLA

Mark Peterson receives inaugural APSA Career Achievement Award in Health Politics and Policy – UCLA

October 23, 2025

Categories

Archives

October 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
« Sep    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (882)
  • Economy (903)
  • Entertainment (21,774)
  • General (17,757)
  • Health (9,944)
  • Lifestyle (916)
  • News (22,149)
  • People (904)
  • Politics (913)
  • Science (16,114)
  • Sports (21,403)
  • Technology (15,883)
  • World (886)

Recent News

Vibrio pectenicida strain FHCF-3 is a causative agent of sea star wasting disease – Nature

Vibrio pectenicida strain FHCF-3 is a causative agent of sea star wasting disease – Nature

October 23, 2025
Condensation defying gravity – European Space Agency

Condensation defying gravity – European Space Agency

October 23, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version